NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD, and related conditions, has appointed Glenn Tyson as its first Chief Commercial Officer. Tyson is joining as the company prepares for anticipated approval of its Abbreviated New Drug Application (ANDA) for a preservative-free ketamine product.
Tyson brings more than 25 years of commercialization and sales experience, including senior leadership roles at GSK and Indivior. At Indivior, he led the successful launch of SUBLOCADE (buprenorphine extended-release injection), a once-monthly injectable for treating opioid addiction.
As Chief Commercial Officer, Tyson will oversee the buildout of market access, distribution, sales, and marketing capabilities to support upcoming product launches and the company’s broader psychiatry pipeline. NRx is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone).
NRX-100 has been awarded Fast Track Designation for treating suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for treating suicidal bipolar depression. NRx has filed an ANDA and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for treating suicidal ideation in patients with depression, including bipolar depression.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/nnwire-2026-4-13-missionirnewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-appoints-first-chief-commercial-officer-ahead-of-ketamine-launch